君实生物(01877.HK)向集合管理计划进行战略配售
格隆汇5月27日丨君实生物(01877.HK)公布,集团部分高级管理人员及核心员工设立集合管理计划参与A股发售项下的战略配售。因此,公司拟与集合管理计划及中金公司(作为A股发售的保荐人及主承销商)订立战略配售协议。
根据配售协议,战略配售项下A股总认购金额将为人民币2.59亿元(包括经纪佣金及税项)。将向集合管理计划发行的A股发行价将与A股发售下的A股发行价相同。将向集合管理计划发行的实际A股数目将按A股最终发行价厘定。集合管理计划将予认购的A股总数不得超过根据A股发售建议发行A股总数的10%。因此,根据战略配售将予发行的最高A股数目为871.3万股A股。集合管理计划将予认购的A股总数不得超过根据A股发售建议发行A股总数的10%。
公告称,设立集合管理计划及战略配售旨在挽留、动员及激励公司员工,并使彼等的利益与股东利益保持一致。参与人为公司高级管理人员及核心员工,彼等各自均在集团的营运及管理中发挥重要作用。参与人亦涵盖公司所有主要职能。公司认为,集合管理计划将有利于挽留参与人,并激励彼等改善公司的业绩。公司亦相信,战略配售将使公司的高级管理人员及核心员工能够参与公司的股权架构,从而促进公司股权架构的多元化及提升企业管治。
公司从战略配售获得的募集资金将与A股发售募集资金的用途一致,即创新药研发、临港生产基地(本集团位于中国上海奉贤区临港产业园的在建中生产基地)建设项目、偿还银行贷款及补充现金流量。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.